We propose to analyze the role of oncogenes in the pathogenesis of human melanoma. Our recent work has shown that 4 out of 40 (10%) cultured human melanoma cell lines have activated transforming genes detectable in the NIH/3T3 assay. Of the 40 melanoma lines assayed, five were from separate metastatic deposits from a single patient. Only 1 of the 5 cell lines from this patient had detectable oncogene activity. The transforming genes derived from the four positive melanoma cell lines were found to belong to the ras gene family, with three isolates related to the N-ras gene and one isolate related to the c-Ha-ras-1 gene. To extend these initial studies, we propose to: (1) determine the frequency of ras gene activation in non-cultured primary and metastatic deposits from different individuals, and in separate multiple primary and metastatic deposits from the same individual. Further, we will investigate p21 levels, p21 species and p21 message in a panel of cultured melanoma cells; (2) determine the presence of transforming non-ras oncogenes in non-cultured and cultured primary and metastatic melanomas; (3) determine the pattern of oncogene expression in cultured and non-cultured primary and metastatic melanomas; and (4) develop transformation assays using human melanocytes and nevus cells. Initial studies will determine optimal conditions for DNA uptake and stable expression and if these cells are competent for transformation by infection with SV40 virus. We will assay the transforming activity of the following cloned genes alone or in combinations: human c-myc, human Ha-ras and adenovirus early region 1A. Studies will also be undertaken to test the transforming activity of human N-ras and c-myc genes cloned into a retroviral experssion vector, pZipNeoSV(X). (X)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA037907-02
Application #
3175849
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
1985-09-01
Project End
1988-08-31
Budget Start
1986-09-01
Budget End
1987-08-31
Support Year
2
Fiscal Year
1986
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Reed, J A; Albino, A P; McNutt, N S (1995) Human cutaneous mast cells express basic fibroblast growth factor. Lab Invest 72:215-22
Fraker, D L; Alexander, H R (1994) The use of tumour necrosis factor (TNF) in isolated perfusion: results and side effects. The NCI results. Melanoma Res 4 Suppl 1:27-9
McNutt, N S; Saenz-Santamaria, C; Volkenandt, M et al. (1994) Abnormalities of p53 protein expression in cutaneous disorders. Arch Dermatol 130:225-32
Reed, J A; McNutt, N S; Prieto, V G et al. (1994) Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression. Am J Pathol 145:97-104
Albino, A P; Vidal, M J; McNutt, N S et al. (1994) Mutation and expression of the p53 gene in human malignant melanoma. Melanoma Res 4:35-45
Reed, J A; McNutt, N S; Albino, A P (1994) Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 144:329-36
Albino, A P; Fountain, J W (1993) Molecular genetics of human malignant melanoma. Cancer Treat Res 65:201-55
Loganzo Jr, F; Dosik, J S; Zhao, Y et al. (1993) Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene 8:2637-44
Morrison, M E; Vijayasaradhi, S; Engelstein, D et al. (1993) A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase. J Exp Med 177:1135-43
Rettig, W J; Garin-Chesa, P; Healey, J H et al. (1993) Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res 53:3327-35

Showing the most recent 10 out of 24 publications